Privately-held Alchemab Therapeutics, a biotech that uses the power of human immune evolution to identify and develop naturally-occurring therapeutic antibodies from resilient individuals, has entered into a licensing agreement with US pharma major Eli Lilly (NYSE: LLY).
The deal is for ATLX-1282, Alchemab’s first-in-class investigational new drug (IND)-ready program for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions.
In total, up to $415 million could be earned by Alchemab from the collaboration, including an undisclosed upfront payment, potential discovery, development and commercialization payments and royalties.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze